ArticleTuberculosis and respiratory diseases2026
Linezolid-Induced Optic Neuritis in Tuberculosis: A Systematic Review of Case Reports, Case Series, and Cohort Studies.
Article in Tuberculosis and respiratory diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Linezolid-Induced Optic Neuritis in Tuberculosis: A Systematic Review of Case Reports, Case Series, and Cohort Studies.Tuberculosis and respiratory diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the increasing use of linezolid for the treatment of drug-resistant tuberculosis, concerns have emerged regarding serious adverse effects, including optic neuritis. To systematically review the available evidence on the incidence of optic neuritis reported in the cohort, its onset, linezolid doses and duration, spectrum, management approaches, and outcomes across case reports and series studies.
methodsA systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines after registration in International Prospective Register of Systematic Reviews (PROSPERO; CRD420251108339). We searched PubMed, EMBASE, and Scopus. Eligible studies included case reports, case series, and cohort studies of patients with tuberculosis who developed optic neuritis while receiving linezolid. Data were extracted independently by two reviewers, and methodological quality was assessed using a validated tool for evaluating case reports and case series. Results were synthesized narratively with descriptive statistics.
resultsNineteen case reports and case series, 35 cohort studies, and safety data from five randomized controlled trials were included. Most reported cases originated from India (61.6%), with a mean age of 30.6±13.0 years; 65.4% were male. Linezolid was administered at 600 mg/day in nearly 90% of cases, with a median exposure of 7 months. Visual symptoms were typically painless and bilateral. After discontinuation of linezolid, more than half of the patients achieved complete visual recovery, while 34.6% experienced residual visual impairment. Across cohort studies, the incidence of optic neuritis ranged from 0.47% to 30%, with higher rates observed in smaller studies from a single country and among patients with a low body mass index.
conclusionThis infrequent but clinically significant complication requires early recognition, prompt drug withdrawal, and routine ophthalmological monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.